Medpace Holdings, Inc. (Nasdaq: MEDP) reported its financial results for the second quarter of 2025, showing a revenue increase of 14.2% to $603.3 million, compared to $528.1 million in the same period of the previous year. The company also reported a GAAP net income of $90.3 million, or $3.10 per diluted share, up from $88.4 million, or $2.75 per diluted share, in the second quarter of 2024. The net income margin stood at 15.0%, compared to 16.7% in the prior-year period. EBITDA reached $130.5 million, marking a 16.2% increase from $112.3 million in the previous year, with an EBITDA margin of 21.6%. For the year-to-date period ending June 30, 2025, Medpace's revenue totaled $1,161.9 million, reflecting an 11.8% increase from the previous year. The year-to-date GAAP net income was $204.9 million, or $6.79 per diluted share, up from $190.9 million, or $5.96 per diluted share, in the previous year. Year-to-date EBITDA increased by 9.3% to $249.1 million, accounting for 21.4% of revenue. The company reported cash and cash equivalents of $46.3 million as of June 30, 2025, and generated $148.5 million in cash flow from operating activities during the second quarter of 2025.